MedTrace Logo

The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis

NCT01496196 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2015-04-14

No results posted yet for this study

Summary

Hemoptysis is defined as the expectoration of blood from respiratory tract, a spectrum that varies from blood-streaking of sputum to coughing up large amounts of pure blood.

Massive hemoptysis variably defined as the expectoration of 100-600 ml over 24-h period.

The most common site of bleeding is the tracheobronchial tree, which can be affected by inflammation (acute or chronic bronchitis, bronchiectasis) or by neoplasm ( bronchogenic carcinoma, endobronchial metastatic carcinoma, bronchial carcinoid tumor). The bronchial arteries, which originate either from aorta or from intercostal arteries, and are part of the high-pressure systemic circulation, are the source of bleeding in bronchitis or bronchiectasis or endo bronchial tumors.

Conditions

  • Hemoptisis

Interventions

DRUG

tranexamic acid

500 mg/5 ml 3-4 times a day

DRUG

tranexamic acid

500 mg/5 ml 3-4 times a day

Sponsors & Collaborators

  • Meir Medical Center

    lead OTHER

Principal Investigators

  • David Shitrit, Dr. · Meir Medical Center, Kfar Saba, Israel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2016-01-31
Completion
2016-02-29

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01496196 on ClinicalTrials.gov